temozolomide has been researched along with Carcinoma, Small Cell Lung in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a phase II study for patients with relapsed small cell lung cancer (SCLC), the administration of Temozolomide, an alkylating agent used in gliomas and anaplastic astrocytoma, showed a effective activity when O(6) -methylguanine-DNA methyltransferase (MGMT) gene promoter was methylated." | 5.20 | Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer. ( Boldorini, R; Buosi, R; Gaudino, E; Mancuso, G; Mercalli, F; Mezzapelle, R; Miglio, U; Paganotti, A; Rena, O; Veggiani, C, 2015) |
| "Temozolomide has activity in relapsed SCLC, particularly for brain metastases." | 2.77 | Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. ( Azzoli, CG; Chan, TA; Fiore, JJ; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Rizvi, NA; Sima, CS; Sumner, DK; Travis, WD, 2012) |
| "Temozolomide was administered at a dose of 75 mg/m/day from days 2-6 and subsequent cohorts were dose escalated by 25 mg/m increments." | 2.76 | Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors. ( Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF, 2011) |
| "As temozolomide has activity in SCLC, we investigated combination therapy with talazoparib and found marked synergy in vitro and efficacy in vivo, which did not solely depend on SLFN11 or MGMT status." | 1.46 | PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. ( de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA, 2017) |
| "BBBD temozolomide was toxic in the efficacy study, but there was no evidence of symptomatic neurotoxicity in rats given IA temozolomide." | 1.43 | Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. ( Muldoon, LL; Netto, JP; Neuwelt, EA; Pagel, MA, 2016) |
| " We therefore evaluated a 5-day dosing schedule of temozolomide and examined MGMT as a predictive biomarker for temozolomide treatment in SCLC." | 1.40 | Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. ( Bergagnini, I; Drilon, A; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Sima, CS; Sumner, DK; Travis, WD; Zauderer, MG, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Stanzione, M | 1 |
| Zhong, J | 1 |
| Wong, E | 1 |
| LaSalle, TJ | 1 |
| Wise, JF | 1 |
| Simoneau, A | 1 |
| Myers, DT | 1 |
| Phat, S | 1 |
| Sade-Feldman, M | 1 |
| Lawrence, MS | 1 |
| Hadden, MK | 1 |
| Zou, L | 1 |
| Farago, AF | 1 |
| Dyson, NJ | 1 |
| Drapkin, BJ | 1 |
| Owen, DH | 1 |
| Benner, B | 1 |
| Pilcher, C | 1 |
| Good, L | 1 |
| Savardekar, H | 1 |
| Norman, R | 1 |
| Ghattas, C | 1 |
| Shah, M | 1 |
| Konda, B | 1 |
| Verschraegen, CF | 2 |
| Wesolowski, R | 1 |
| Behbehani, GK | 1 |
| Carson, WE | 1 |
| Otterson, GA | 1 |
| Pietanza, MC | 4 |
| Waqar, SN | 1 |
| Krug, LM | 4 |
| Dowlati, A | 1 |
| Hann, CL | 1 |
| Chiappori, A | 1 |
| Owonikoko, TK | 2 |
| Woo, KM | 1 |
| Cardnell, RJ | 1 |
| Fujimoto, J | 1 |
| Long, L | 1 |
| Diao, L | 1 |
| Wang, J | 1 |
| Bensman, Y | 1 |
| Hurtado, B | 1 |
| de Groot, P | 1 |
| Sulman, EP | 1 |
| Wistuba, II | 1 |
| Chen, A | 1 |
| Fleisher, M | 1 |
| Heymach, JV | 1 |
| Kris, MG | 3 |
| Rudin, CM | 2 |
| Byers, LA | 1 |
| Sidaway, P | 1 |
| Pujol, JL | 1 |
| Roch, B | 1 |
| Pujol, CN | 1 |
| Goze, C | 1 |
| Nazha, B | 1 |
| Zauderer, MG | 1 |
| Drilon, A | 1 |
| Kadota, K | 2 |
| Huberman, K | 2 |
| Sima, CS | 2 |
| Bergagnini, I | 1 |
| Sumner, DK | 2 |
| Travis, WD | 2 |
| Heguy, A | 2 |
| Ginsberg, MS | 2 |
| Holodny, AI | 2 |
| Riely, GJ | 2 |
| Miglio, U | 1 |
| Mezzapelle, R | 1 |
| Paganotti, A | 1 |
| Veggiani, C | 1 |
| Mercalli, F | 1 |
| Mancuso, G | 1 |
| Gaudino, E | 1 |
| Rena, O | 1 |
| Buosi, R | 1 |
| Boldorini, R | 1 |
| Muldoon, LL | 1 |
| Pagel, MA | 1 |
| Netto, JP | 1 |
| Neuwelt, EA | 1 |
| Lok, BH | 1 |
| Gardner, EE | 1 |
| Schneeberger, VE | 1 |
| Ni, A | 1 |
| Desmeules, P | 1 |
| Rekhtman, N | 1 |
| de Stanchina, E | 1 |
| Teicher, BA | 1 |
| Riaz, N | 1 |
| Powell, SN | 1 |
| Poirier, JT | 1 |
| Hiddinga, BI | 1 |
| Pauwels, P | 1 |
| Janssens, A | 1 |
| van Meerbeeck, JP | 1 |
| Zauderer, M | 1 |
| O'Rourke, D | 1 |
| Movva, S | 1 |
| Rabinowitz, I | 1 |
| Mangalik, A | 1 |
| Parks, V | 1 |
| Lee, FC | 1 |
| Fiore, JJ | 1 |
| Chan, TA | 1 |
| Rizvi, NA | 1 |
| Azzoli, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors[NCT03728361] | Phase 2 | 55 participants (Actual) | Interventional | 2018-12-31 | Active, not recruiting | ||
| A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer[NCT01638546] | Phase 2 | 97 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Tabulated According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0. Summary level. (NCT01638546)
Timeframe: From the start of treatment until 30 days from coming off treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Veliparib and Temozolomide) | 52 |
| Arm II (Placebo and Temozolomide) | 45 |
Corresponding exact two-sided 95% confidence intervals will be calculated and reported in both arms of the study. Comparisons between treatment arms will be performed using Fisher-exact test. (NCT01638546)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 months
| Intervention | participants (Number) |
|---|---|
| Arm I (Veliparib and Temozolomide) | 20 |
| Arm II (Placebo and Temozolomide) | 6 |
Estimated in each treatment group using Kaplan-Meier method. Group comparisons will be performed using log-rank test. (NCT01638546)
Timeframe: From randomization to time of death
| Intervention | months (Median) |
|---|---|
| Arm I (Veliparib and Temozolomide) | 8.2 |
| Arm II (Placebo and Temozolomide) | 7 |
Compared across the two arms using a Fisher exact test. (NCT01638546)
Timeframe: From randomization to time of progression or death, whichever occurs first, assessed at 4 months
| Intervention | participants (Number) |
|---|---|
| Arm I (Veliparib and Temozolomide) | 18 |
| Arm II (Placebo and Temozolomide) | 11 |
2 reviews available for temozolomide and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aurora Kinase A; Benzodiazepinones; Dacarb | 2018 |
O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; | 2017 |
4 trials available for temozolomide and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2018 |
Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Dacarbazine; DNA Methylation; Glioma; Guanine; | 2015 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazin | 2011 |
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; DNA Meth | 2012 |
8 other studies available for temozolomide and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.
Topics: Cell Line, Tumor; DNA; DNA Damage; DNA Replication; Humans; Lung Neoplasms; Phthalazines; Piperazine | 2022 |
Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Male; Myeloid-Derived | 2021 |
SLFN11: a new synthetic lethal target?
Topics: Benzimidazoles; Double-Blind Method; Humans; Lung Neoplasms; Nuclear Proteins; Small Cell Lung Carci | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplas | 2019 |
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration | 2014 |
Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug | 2016 |
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin | 2017 |
Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lung Neoplasms; Mal | 2010 |